Constipation Is Not Attributable to Low‑Dose Vaginal Estradiol Cream

Systemic Absorption and Localized Safety Profile

Low‑dose vaginal estradiol (0.01%) results in minimal systemic absorption and does not raise serum estradiol to clinically significant levels, indicating a primarily local effect. 1
Because the medication acts locally on vaginal tissues, its side‑effect profile differs markedly from oral or systemic estrogen therapy; gastrointestinal adverse events such as constipation have not been reported. 1

In large randomized controlled trials of an even lower concentration (0.003%) estradiol vaginal cream, the most frequent adverse event was vulvovaginal mycotic infection, with no cases of constipation observed. 1

Constipation is a recognized adverse effect of oral anticholinergic agents (e.g., solifenacin, tolterodine) used for overactive bladder, as documented in urology guidelines. 2
Combination therapy studies of solifenacin + mirabegron for overactive bladder specifically identified constipation as an adverse event, reflecting the impact of oral anticholinergics—not vaginal estrogen. 2

When a postmenopausal woman using estradiol vaginal cream 0.01% develops constipation, clinicians should investigate alternative causes (dietary factors, fluid intake, physical inactivity, other medications such as opioids or anticholinergics, or underlying medical conditions) rather than attributing the symptom to the vaginal estrogen. 1
The overall safety profile of low‑dose vaginal estrogen is favorable, with demonstrated endometrial safety (no increased risk of hyperplasia or carcinoma) and minimal systemic hormonal effects. 1